Nuclear transcription factors: new opportunities for lipid lowering.
Staels
B
B
U325 INSERM, Département d'Athérosclérose, Institut Pasteur de Lille and Faculté de Pharmacie, Université de Lille, France. Bart.Staels@pasteur-lille.fr
D000818:Animals; D008076:Cholesterol, HDL / Q000187:drug effects / Q000378:metabolism*; D003327:Coronary Disease / Q000517:prevention & control*; D006801:Humans; D000960:Hypolipidemic Agents; D018160:Receptors, Cytoplasmic and Nuclear / Q000502:physiology*; D013631:Tangier Disease / Q000188:drug therapy*; D014157:Transcription Factors / Q000502:physiology*
D008076:Cholesterol, HDL; D000960:Hypolipidemic Agents; D018160:Receptors, Cytoplasmic and Nuclear; D014157:Transcription Factors